AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01970176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
Study NCT03625388 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Film coated tablet contains dasatinib monohydrate
Study NCT03345186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse led plus standard of care
Description: structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
Study NCT01848145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of >= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE >= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
Study NCT05586126 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: sevoflurane inhalation
Study NCT04168294 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: patients in sedation group will be intravenous injected propofol in bolus
Study NCT04168294 — intervention group
Intervention type: DEVICE
Intervention: endoscopy
Description: endoscopy system
Study NCT04177290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab (M1b)
Description: Intravenous infusion
Study NCT04177290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab (approved)
Description: Intravenous infusion
Study NCT00595166 — intervention group
Intervention type: DEVICE
Intervention: Vaginal Speculum Sheath
Description: Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
Study NCT02374853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Topical prophylactic antibiotic
Study NCT02374853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Vancomycin
Description: Placebo: Sterile water. No Vancomycin.
Study NCT00924326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m\^2 intravenous (IV) over 30 minutes
Study NCT00924326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
Study NCT00924326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-cluster of differentiation 19 (CD19)-CAR PBL
Description: Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) peripheral blood lymphocytes ( PBL).~Day 0 (two to four days after the last dose of fludarabine); Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes.
Study NCT00924326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
Study NCT00924326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m\^2 intravenous (IV) over 30 minutes
Study NCT00924326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -5 to -3: 300mg/m\^2 intravenous (IV) over 60 minutes
Study NCT01333332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine
Study NCT01333332 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Dose Acclerated Fraction Radiotherapy
Description: Standard dose accelerated fraction radiotherapy
Study NCT03897751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABT12 Multi-Purpose Solution
Description: Contact lens cleaning and disinfecting solution
Study NCT03897751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COMPLETE Multi-Purpose Solution
Description: Contact lens cleaning and disinfecting solution
Study NCT03897751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensitive Eyes® Rewetting Drops
Description: For use as needed during the study.
Study NCT03897751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensitive Eyes® Rewetting Drops
Description: For use as needed during the study.
Study NCT02111278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
Study NCT02843997 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Endophenotype and sequencing
Description: Draw an endophenotype and genetic study
Study NCT01757145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count \< 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count >50,000/microliter will be reached again).
Study NCT03997227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae Block
Description: After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
Study NCT03430713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of tooth color
Description: Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
Study NCT03276169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
Study NCT01710657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 50 mg
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study NCT01710657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 100 mg
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 100 mg~* Route of Administration: Oral use
Study NCT01710657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral Placebo tablets twice daily for 16 weeks.
Study NCT00038675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec)
Description: Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
Study NCT00184600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
Study NCT00184600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
Study NCT03276169 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation
Description: Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
Study NCT03276169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation group
Description: Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
Study NCT03072160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.
Study NCT01091571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days
Study NCT01091571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily during seven consecutive days
Study NCT01091571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Description: The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
Study NCT01091571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LPS
Description: The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
Study NCT01577238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: Vaginal gel, daily for 7 days
Study NCT01577238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal gel, daily for 7 days
Study NCT00184600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
Study NCT00006365 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT00006365 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 125
Study NCT00006365 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03363503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Capsair®
Description: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
Study NCT03363503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/Fluticasone Diskus®
Description: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
Study NCT04697017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
Description: The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
Study NCT00322621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT01704612 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ropivacaine
Description: patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
Study NCT01704612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
Study NCT04272112 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max CAD, Ivoclar Vivadent
Description: Type: monolithic lithium-disilicate glass ceramic
Study NCT04272112 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BruxZir, Glidewell
Description: Type: high translucent zirconia
Study NCT04272112 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BruxZir*, Glidewell
Description: Type: high translucent zirconia with a mini-veneer of porcelain
Study NCT03409978 — intervention group
Intervention type: DEVICE
Intervention: in-Motion app
Description: mobile phone application for recording fidgety movements at home
Study NCT02294760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subsensory
Description: The stimulation is set to 90% of the sensory threshold.
Study NCT05281822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The stress management training
Description: The women in the experimental group were provided with stress management training to help cope with stress conditions how to use positive coping in conditions in case of stress and tension.
Study NCT02698982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)
Study NCT02698982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moderate risk surgery
Study NCT02698982 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: moderate risk surgery
Study NCT04608253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 11C-choline PET/CT
Description: 11C-choline PET/CT
Study NCT03314298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone anastrozole
Description: subcutaneous testosterone and anastrozole
Study NCT03923465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Periodontal surgery with entire papilla preservation (EPP) technique
Description: After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
Study NCT03923465 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure: Periodontal surgery with entire papilla preservation (EPP) technique
Description: After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
Study NCT03923465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMD application
Description: Application of Pref-Gel for 2 minutes and then the application of Enamel Matrix Derivatives (EMD) on the surgically exposed root surface.
Study NCT03923465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone substitutes application
Description: Following the application of EMD, filling the bone defect with bone substitutes.
Study NCT04334174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
Study NCT02023853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonic
Study NCT02294760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OFF
Description: The stimulation is turned OFF.
Study NCT01038869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
Study NCT00021073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00021073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00021073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00021073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00977457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
Study NCT00977457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
Study NCT00977457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
Study NCT00977457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
Study NCT03118947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
Study NCT01261819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cystoscopy
Study NCT01261819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cystoscopy
Study NCT02502760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program
Description: Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
Study NCT02502760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise Program
Description: Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
Study NCT02502760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate Powder
Description: Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses
Study NCT02502760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Isolate Powder
Description: Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses
Study NCT02502760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Techniques
Description: Relaxation techniques consisting of breathing exercises and using a relaxation CD.
Study NCT02502760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Techniques
Description: Relaxation techniques consisting of breathing exercises and using a relaxation CD.
Study NCT00977457 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery